Targeted therapy and new anticancer drugs in advanced disease

Thoracic Surgery Clinics

Volumn 23, Issue 3, 2013, Pages 411-419

  Silva, Shobha ^a   Danson, Sarah ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Advanced lung cancer; Non small cell lung cancer; Small cell lung cancer; Targeted agents

Indexed keywords

AFATINIB; AGATOLIMOD; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; CYCLOOXYGENASE 2 INHIBITOR; DABRAFENIB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; OBATOCLAX; ONARTUZUMAB; PACLITAXEL; SELUMETINIB; SORAFENIB; TEMSIROLIMUS; THALIDOMIDE; TIVANTINIB; UNINDEXED DRUG; VANDETANIB; VORINOSTAT;

ADVANCED CANCER; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DIARRHEA; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INTERSTITIAL PNEUMONIA; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SKIN TOXICITY; SYSTEMIC THERAPY; THROMBOSIS; VISUAL DISORDER;

ADVANCED LUNG CANCER; NON-SMALL CELL LUNG CANCER; SMALL CELL LUNG CANCER; TARGETED AGENTS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84881374800     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2013.05.008     Document Type: Review

References (68)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311(7010):899-909.
2. Schiller J.H., Harrington D., Chandra P.B., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. NEngl J Med 2002, 346:92-98.
3. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. NEngl J Med 2005, 353:123-132.
4. Clark G.M., Zborowski D.M., Santabarbara P., et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006, 7:389-394.
5. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
6. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. JClin Oncol 2005, 23:5892-5899.
7. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. JClin Oncol 2007, 25:1545-1552.
8. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinumbased chemotherapy in patients with advanced NSCLC. JClin Oncol 2009, 27(Suppl):S15.
9. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEngl J Med 2004, 350:2129.
10. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumours to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306.
11. Fukuoka M., Wu Y.L., Thongprasert S., et al. Biomarker analysis and final overall survival results from a phase III, randomised, open label, first line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). JClin Oncol 2011, 29:2866.
12. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009, 373:1525-1531.
13. Yang J.C., Schuler M.H., Yamamoto M., et al. LUX-Lung 3: a randomised, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harbouring EGFR activating mutations. [abstract LBA7500]. JClin Oncol 2012, 30(Suppl).
14. Miller V.A., Hirsh V., Cadranel J., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13(5):528-538.
15. Food and Drug Administration. Available at:. Accessed January, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/20270s000lbl.pdf.
16. Shaw A.T., Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011, 17:2081.
17. Rodig S.J., Mino-Kenudson M., Docic S., et al. Unique clinicopathologic features characterise ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216.
18. Soda M., Choi Y.L., Enomoto M., et al. Identification of the EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561.
19. Inamura K., Takeuchi K., Togashi Y., et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. JThorac Oncol 2008, 3:13.
20. Martelli M.P., Sozzi G., Hernandez L., et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009, 40:1152.
21. Shaw A.T., Yeap B.Y., Mino-Kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbour EML4-ALK. JClin Oncol 2009, 27:4247-4253.
22. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. NEngl J Med 2010, 363:1693.
23. Camidge D.R., Bang Y., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK positive non-small-cell lung cancer: updated results from a phase I study. Lancet Oncol 2012, 13(10):1011-1019.
24. Shaw AT, Kim DW, Nakagawa K, etal. Phase III study of crizotinnib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer [abstract LBA1 PR]. Presented at the 37th Congress of the European Society of Medical Oncology(ESMO), Vienna, Austria, September 28- October 2, 2012.
25. Danson S. Targeted therapy in non-small cell lung cancer. Non-small cell lung cancer therapy 2010, 143-150. UniMedScience, Bremen (Germany). 2nd edition. C. Manegold (Ed.).
26. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Clin Oncol 2004, 22(11):2184-2191.
27. Sandler A.B., Gray R., Brahmer J., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer (NSCLC). NEngl J Med 2006, 355:2542-2550.
28. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. JClin Oncol 2009, 27:1227-1234.
29. Natale R.B., Thongprasert S., Greco A., et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). JClin Oncol 2009, 27(Suppl):15s. [abstract 8009].
30. Lee J.S., Hirsh V., Park K., et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). JClin Oncol 2012, 30(10):1114-1121.
31. Xiao Y.Y., Zhan P., Yuan D.M. Chemotherapy plus vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials. Clin Oncol (R Coll Radiol) 2013, 25(1):e7-e15. 10.1016/j.clon.2012.09.005.
32. Lee S.M., Rudd R., Woll P.J., et al. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer. JClin Oncol 2009, 27(31):5248-5254.
33. Suzuki Y., Orita M., Shiraishi M., et al. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990, 5(7):1037-1043.
34. Schiller J.H., Adak S., Feins R.H., et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. JClin Oncol 2001, 19(2):448-457.
35. Ahrendt S.A., Decker P.A., Alawi E.A. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001, 92(6):1525.
36. Johnson M.L., Sima C.S., Chaft J., et al. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer 2013, 119(2):356-362.
37. Appels N.M., Beijnen J.H., Schellens J.H. Development of farnesyl transferase inhibitors: a review. Oncologist 2005, 10(8):565-578.
38. Riely G.J., Johnson M.L., Medina C., et al. Aphase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations. JThorac Oncol 2011, 6(8):1435-1437.
39. Janne P.A., Shaw A.T., Rodrigues Pereira J., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14(1):38-47.
40. Scagliotti G., Novello S., von P.J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer. JClin Oncol 2010, 28(11):1835-1842.
41. Liu P., Cheng H., Roberts T.M., et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8(8):627-644.
42. Molina J.R., Mandrekar S.J., Rowland K.R. Aphase II NCCTG "window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC. JThorac Oncol 2007, 2(Suppl 4):S413.
43. Papadimitrakopoulou V., Adjei A.A. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. JThorac Oncol 2006, 1:749-751.
44. Leighl N.B., Soria J., Bennouna J., et al. Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). JClin Oncol 2010, 28(Suppl):15s. [abstract 7524].
45. Nakamura Y., Niki T., Goto A., et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 2007, 98(7):1006-1013.
46. Ichimura E., Maeshima A., Nakajima T., et al. Expression of c-met/HGF receptor in human non-small cell lung carcinomas invitro and invivo and its prognostic significance. Jpn J Cancer Res 1996, 87(10):1063.
47. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
48. Groen H.J., Sietsma H., Vincent A., et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. JClin Oncol 2011, 29(32):4320-4326.
49. Koch A., Bergman B., Holmberg E., et al. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer 2011, 47(10):1546-1555.
50. Ramalingam S.S., Maitland M.L., Frankel P., et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. JClin Oncol 2010, 28(1):56-62.
51. Besse B., Planchard D., Veillard A.S., et al. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer 2012, 76(1):78-83.
52. Fanucchi M.P., Fossella F.V., Belt R., et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. JClin Oncol 2006, 24(31):5025-5033.
53. Davies A.M., Chansky K., Lara P.N., et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II southwest oncology group study (S0339). JThorac Oncol 2009, 4(1):87-92.
54. Scagliotti G.V., Germonpré P., Bosquée L., et al. Arandomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010, 68(3):420-426.
55. Lynch T.J., Fenton D., Hirsh V., et al. Arandomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. JThorac Oncol 2009, 4(8):1002-1009.
56. Decoster L., Wauters I., Vansteenkiste J.F. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol 2012, 23:1387-1393.
57. Moore A.M., Einhorn L.H., Estes D., et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006, 52:93-97.
58. Lu H.Y., Wang X.J., Mao W.M. Targeted therapies in small cell lung cancer. Oncol Lett 2013, 5(1):3-11.
59. Horn L., Dahlberg S.E., Sandler A.B., et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. JClin Oncol 2009, 27(35):6006-6011.
60. Spigel D.R., Townley P.M., Waterhouse D.M., et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. JClin Oncol 2011, 29:2215-2222.
61. Jalal S., Bedano P., Einhorn L., et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. JThorac Oncol 2010, 5:2008-2011.
62. Arnold A.M., Seymour L., Smylie M., et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. JClin Oncol 2007, 25(27):4278.
63. Lee S.M., Woll P.J., Rudd R., et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. JNatl Cancer Inst 2009, 101(15):1049.
64. Pujol J.L., Breton J.L., Gervais R., et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. JClin Oncol 2007, 25(25):3945.
65. Langer C.J., Albert I., Kovacs P., et al. Arandomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC). JClin Oncol 2011, 29(Suppl). [abstract 7001].
66. Rudin C.M., Salgia R., Wang X., et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. JClin Oncol 2008, 26:870-876.
67. Nakanishi Y., Mulshine J.L., Kasprzyk P.G., et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines invitro. JClin Invest 1988, 82(1):354.
68. Reck M., Bondarenko I., Luft A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013, 24(1):75-83.